What is the current analyst consensus on the stock after the release—upgrades, downgrades, or rating changes? | AMN (Aug 07, 2025) | Candlesense
AMN

What is the current analyst consensus on the stock after the release—upgrades, downgrades, or rating changes?

Answer

The press release you provided reports AMN Healthcare’s Q2 2025 financial results (revenue of $658 million, adjusted EBITDA of $58.3 million, GAAP loss of ($3.02) per share, and adjusted EPS of $0.30). However, it does not contain any information about analyst activity—such as upgrades, downgrades, or rating changes—following the earnings announcement.

What this means for your question

  • No analyst consensus is disclosed in the excerpt you shared.
  • Without additional coverage (e.g., analyst notes, brokerage research updates, or market commentary) we cannot determine whether analysts have changed their ratings, issued upgrades, or issued downgrades after the results were released.

How to find the current analyst consensus

  1. Check financial newswire services (e.g., Bloomberg, Reuters, FactSet) for “analyst actions” or “rating changes” tied to the ticker AMN on or after 2025‑08‑07.
  2. Visit brokerage research portals (e.g., Thomson Reuters IHS, S&P Capital IQ, or the “Research” tab on major broker websites) that track rating updates in real time.
  3. Look at market data platforms (e.g., Yahoo Finance, MarketWatch, or Google Finance) that often list a “Consensus rating” (Buy/Hold/Sell) and note recent upgrades/downgrades.
  4. Search for press releases or analyst reports titled “AMN Healthcare analyst upgrade” or “AMN Healthcare rating change” dated 2025‑08‑07 or later.

Bottom line: Based solely on the earnings release you provided, we cannot answer whether analysts have upgraded, downgraded, or otherwise changed their rating on AMN Healthcare. You’ll need to consult a source that tracks analyst activity to obtain the current consensus.

Other Questions About This News

What was the immediate market reaction (price movement, volume) to the release and how does that compare to typical earnings reactions for AMN? What macro‑economic factors (e.g., labor market conditions, healthcare spending, staffing demand) could influence future results? How did the company’s operating margin change year‑over‑year and what cost drivers are influencing it? Did the company provide guidance for Q3 2025 revenue, EPS, and Adjusted EBITDA, and how does that compare to analyst expectations? What contributed to the Adjusted EBITDA of $58.3 million and how does this compare to previous quarters? What were the main drivers behind the GAAP loss of $3.02 per share? What are the implications of the GAAP loss versus the positive adjusted EPS for valuation metrics (P/E, EV/EBITDA), and how might investors re‑price the stock? How does AMN’s Q2 performance compare to peers such as Cross Country Healthcare, Envision Healthcare, or other staffing firms? How did AMN Healthcare’s Q2 2025 revenue of $658 million compare to consensus estimates? Did AMN disclose any changes to its capital allocation strategy—share repurchases, dividends, or acquisitions? Did the earnings release mention any regulatory or policy changes that may affect revenue or margins? What was the consensus EPS estimate for Q2 2025 and how does the reported adjusted EPS of $0.30 compare? What changes in key operational metrics (e.g., placements, revenue per employee, utilization rates) were highlighted that could affect future performance? What full‑year 2025 guidance did AMN give for revenue, profit and cash flow, and how does it align with market expectations? Are there any updates to the company’s debt profile, cash balance, or liquidity position?